SEC 13F Intelligence

Commodore Capital LP / XENE

Commodore Capital LP’s Xenon Pharmaceuticals Inc Position

Does Commodore Capital LP own Xenon Pharmaceuticals Inc (XENE)? Yes825.0K shares worth $48M (+2.78% of its 13F portfolio) as of Q1 2026, down from 1.80M shares the prior filed quarter.

Position Value
$48M
Q1 2026
Shares
825.0K
% of Portfolio
+2.78%
Quarters Held
22
currently held

Position History XENE

Reported value by quarter
Q4 ’20: $7MQ4 ’20Q1 ’21: $5MQ2 ’21: $6MQ3 ’21: $9MQ3 ’21Q4 ’21: $34MQ1 ’22: $37MQ2 ’22: $49MQ2 ’22Q3 ’22: $58MQ4 ’22: $65,419Q1 ’23: $66MQ1 ’23Q2 ’23: $71MQ3 ’23: $63MQ4 ’23: $100MQ4 ’23Q1 ’24: $93MQ2 ’24: $107MQ3 ’24: $106MQ3 ’24Q4 ’24: $107MQ1 ’25: $78MQ2 ’25: $95MQ2 ’25Q3 ’25: $108MQ4 ’25: $81MQ1 ’26: $48MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026825.0K$48M+2.78%
Q4 20251.80M$81M+5.37%
Q3 20252.70M$108M+5.29%
Q2 20253.02M$95M+6.68%
Q1 20252.33M$78M+5.75%
Q4 20242.74M$107M+7.87%
Q3 20242.70M$106M+6.64%
Q2 20242.75M$107M+7.33%
Q1 20242.17M$93M+6.24%
Q4 20232.17M$100M+8.72%
Q3 20231.84M$63M+7.37%
Q2 20231.84M$71M+7.98%
Q1 20231.84M$66M+10.05%
Q4 20221.66M$65,419+9.86%
Q3 20221.59M$58M+9.26%
Q2 20221.59M$49M+10.26%
Q1 20221.20M$37M+8.21%
Q4 20211.09M$34M+7.89%
Q3 2021579.4K$9M+2.33%
Q2 2021326.3K$6M+2.09%
Q1 2021301.4K$5M+2.12%
Q4 2020467.4K$7M+3.91%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Commodore Capital LP’s full portfolio or all institutional holders of XENE.